Neurocrine Biosciences Inc

NAS:NBIXHealthcareNASDAQ:NBINASDAQ:NQUSMG

$136.98+0.94%At closeAt close · Tue 20 Oct · ≈ AED 503.06 · Market cap $13.92B · Next earnings Tue 27 Oct

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	99.0%	98.7%	98.4%	97.9%	98.6%	98.2%	—	—
Operating margin	15.6%	9.0%	16.7%	13.3%	24.2%	21.6%	21.6%	+0.0 pts
Net margin	38.9%	7.9%	10.4%	13.2%	14.5%	16.7%	16.7%	+0.0 pts
EBITDA margin	14.2%	12.2%	15.9%	22.0%	27.2%	23.3%	—	—
Return on equity	36.2%	6.5%	9.0%	11.2%	13.2%	14.7%	14.7%	+0.0 pts
Return on assets	23.5%	4.3%	6.5%	7.7%	9.2%	10.3%	10.3%	+0.0 pts
Return on capital employed	10.5%	5.6%	13.6%	9.7%	17.8%	15.9%	—	—
Debt / equity	0.4×	0.3×	0.2×	0.2×	0.2×	0.1×	0.1×	+0.0%
Debt / assets	23.8%	21.2%	11.1%	13.2%	12.2%	9.0%	—	—
Interest coverage	5.0×	4.0×	35.1×	54.5×	4.5×	0.0×	—	—
Current ratio	5.4×	4.0×	2.7×	2.5×	3.4×	3.4×	3.4×	+0.0%
Quick ratio	5.3×	3.8×	2.6×	2.4×	3.3×	3.3×	—	—
Cash ratio	1.0×	1.4×	0.5×	0.4×	0.5×	1.0×	1.0×	+0.0%
Asset turnover	0.6×	0.5×	0.6×	0.6×	0.6×	0.6×	—	—
Inventory turnover	0.4×	0.5×	0.7×	1.0×	0.6×	0.8×	—	—
Receivables turnover	6.7×	6.1×	4.3×	4.3×	4.9×	4.2×	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—

Margins, returns, leverage and liquidityUpdated 31 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.